| Ident. | Authors (with country if any) | Title |
|---|
| 000086 |
Stéphane Thobois [France] ; Eugénie Lhommee [France] ; Hélène Klinger [France] ; Claire Ardouin [France] ; Emmanuelle Schmitt [France] ; Amélie Bichon [France] ; Andrea Kistner [France] ; Anna Castrioto [France] ; JING XIE [France] ; Valerie Fraix [France] ; Pierre Pelissier [France] ; Stephan Chabardes [France] ; Patrick Mertens [France] ; Jean-Louis Quesada [France] ; Jean-Luc Bosson [France] ; Pierre Pollak [France] ; Emmanuel Broussolle [France] ; Paul Krack [France] | Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil |
| 000507 |
A. Faure [France] ; P. Leblanc-Veyrac [France] ; N. El Massioui [France] | DOPAMINE AGONISTS INCREASE PERSEVERATIVE INSTRUMENTAL RESPONSES BUT DO NOT RESTORE HABIT FORMATION IN A RAT MODEL OF PARKINSONISM |
| 000856 |
Dieter Scheller [Allemagne] ; PIU CHAN [République populaire de Chine] ; QIN LI [Royaume-Uni] ; TAO WU [République populaire de Chine] ; RENLING ZHANG [République populaire de Chine] ; LE GUAN [République populaire de Chine] ; Paula Ravenscroft [Royaume-Uni] ; Celine Guigoni [France] ; Alan R. Crossman [Royaume-Uni] ; Michael Hill [Royaume-Uni] ; Erwan Bezard [France] | Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease |
| 000A33 |
Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France] | Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets : Mediation by D2, not D3, dopamine receptors |
| 000A35 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000C12 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000C14 |
Paula Ravenscroft [Royaume-Uni] ; Sylvie Chalon [France] ; Jonathan M. Brotchie [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] | Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia |
| 000D22 |
J.-L. Montastruc [France] ; L. Schmitt [France] ; H. Bagheri [France] | Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine |
| 000D42 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000D49 |
Roberto Maggio [Italie] ; Marco Scarselli [Italie] ; Francesca Novi [Italie] ; Mark J. Millan [France] ; Giovanni U. Corsini [Italie] | Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole |
| 000D57 |
Jeffrey N. Joyce [États-Unis] ; Steve Presgraves [États-Unis] ; Lynn Renish [États-Unis] ; Sabinne Borwege [États-Unis] ; Tracy Osredkar [États-Unis] ; Diane Hagner [États-Unis] ; Maria Replogle [États-Unis] ; Mateo Pazsoldan [États-Unis] ; Mark J. Millan [France] | Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole |
| 000E33 |
O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France] | Prise en charge des dyskinésies par la lévodopa |
| 000F34 |
A. Angles [France] ; H. Bagheri [France] ; S. Saivin [France] ; J. L. Montastruc [France] | Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease |
| 000F48 |
A. D. Korczyn [Israël] ; C. Thalamas [France] ; C. H. Adler [États-Unis] | Dosing with ropinirole in a clinical setting |
| 000F51 |
Diego Centonze [Italie] ; Alessandro Usiello [France] ; Paolo Gubellini [Italie] ; Antonio Pisani [Italie] ; Emiliana Borrelli [France] ; Giorgio Bernardi [Italie] ; Paolo Calabresi [Italie] | Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors |
| 000F80 |
K. Ray Chaudhuri [Royaume-Uni] ; Suvankar Pal [Royaume-Uni] ; Christine Brefel-Courbon [France] | 'Sleep attacks' or 'Unintended sleep episodes' occur with dopamine agonists: Is this a class effect? |
| 001030 |
Jean-Louis Montastruc [France] ; Christine Brefel-Courbon [France] ; Jean-Michel Senard [France] ; Haleh Bagheri [France] ; Joaquim Ferreira [France] ; Olivier Rascol [France] ; Maryse Lapeyre-Mestre [France] | Sleep attacks and antiparkinsonian drugs : A pilot prospective pharmacoepidemiologic study |
| 001081 |
Adrian Newman-Tancredi [France] ; Didier Cussac [France] ; Mauricette Brocco [France] ; Jean-Michel Rivet [France] ; Christine Chaput [France] ; Manuelle Touzard [France] ; Valérie Pasteau [France] ; Mark J. Millan [France] | Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra |
| 001143 |
O. Rascol [France] ; J.-L. Montastruc [France] | La place des agonistes dopaminergiques |
| 001172 |
L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni] | Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset |
| 001177 |
M. G. Murer [France, Argentine] ; G. Dziewczapolski [Argentine] ; P. Salin [France] ; M. Vila [France] ; K. Y. Tseng [Argentine] ; M. Ruberg [France] ; M. Rubinstein [Argentine] ; M. A. Kelly [États-Unis] ; D. K. Grandy [États-Unis] ; M. J. Low [États-Unis] ; E. Hirsch [France] ; R. Raisman-Vozari [France] ; O. Gershanik [Argentine] | The indirect basal ganglia pathway in dopamine D2 receptor-deficient mice |
| 001196 |
O. Rascol [France] | Medical treatment of levodopa-induced dyskinesias |
| 001242 |
D. C. Rogers [Royaume-Uni] ; B. Costall [Royaume-Uni] ; A. M. Domeney [France] ; P. A. Gerrard [Royaume-Uni] ; M. Greener [Royaume-Uni] ; M. E. Kelly [Royaume-Uni] ; J. J. Hagan [Royaume-Uni] ; A. J. Hunter [Royaume-Uni] | Anxiolytic profile of ropinirole in the rat, mouse and common marmoset |
| 001248 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 001303 |
C. Dentresangle [France] ; L. Veyre [France] ; D. Le Bars [France] ; C. Pierre [France] ; F. Lavenne [France] ; P. Pollak [France] ; J. Guerin [France] ; J.-C. Froment [France] ; E. Brousolle [France] | Striatal D2 dopamine receptor status in Parkinson's disease : An [18F]dopa and [11C]raclopride PET study |
| 001332 |
M. G. Murer [Argentine] ; J. Ferrario [Argentine] ; M. Delfino [Argentine] ; G. Dziewczapolski [Argentine] ; O. S. Gershanik [Argentine] ; R. Raisman-Vozari [France] | Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions |
| 001342 |
| Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients |
| 001351 |
F. A. Dajas-Bailador [Uruguay] ; M. Asencio [Chili] ; C. Bonilla [Uruguay] ; M. C. Scorza [Uruguay] ; C. Echeverry [Uruguay] ; M. Reyes-Parada [Uruguay] ; R. Silveira [Uruguay] ; P. Protais [France] ; G. Russell [Nouvelle-Zélande] ; B. K. Cassels [Chili] ; F. Dajas [Uruguay] | Dopaminergic pharmacology and antioxidant properties of pukateine, a natural product lead for the design of agents increasing dopamine neurotransmission |
| 001355 |
S. Champagne [France] ; E. Coste [France] ; H. Peyriere [France] ; J. Nigond [France] ; E. Mania [France] ; M. Pons [France] ; D. Hillaire-Buys [France] ; P. Balmes [France] ; J.-P. Blayac [France] ; J.-M. Davy [France] | Chronic constrictive pericarditis induced by long-term bromocriptine therapy : Report of two cases |
| 001386 |
O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France] | Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens |
| 001416 |
A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie] | The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease |
| 001421 |
A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study |
| 001422 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study |
| 001444 |
W. Krezel [France] ; N. Ghyselinck [France] ; T. A. Samad [France] ; V. Dupe [France] ; P. Kastner [France] ; E. Borrelli [France] ; P. Chambon [France] | Impaired locomotion and dopamine signaling in retinoid receptor mutant mice |
| 001454 |
C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France] | Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients |
| 001469 |
D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni] | A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease |
| 001543 |
Yves Agid [France] ; A. Destee ; F. Durif ; J.-L. Montastruc ; P. Pollak | Tolcapone, bromocriptine, and Parkinson's disease |
| 001568 |
N. B. Mercuri [Italie] ; A. Saiardi [France] ; A. Bonci [Italie] ; R. Picetti [France] ; P. Calabresi [Italie] ; G. Bernardi [Italie] ; E. Borrelli [France] | Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice |
| 001579 |
V. Plante-Bordeneuve [France] ; D. Taussig [France] ; F. Thomas [France] ; G. Said [France] ; N. W. Wood [Royaume-Uni] ; C. D. Marsden [Royaume-Uni] ; A. E. Harding [Royaume-Uni] | Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease : Evidence for association of a DRD2 allele |
| 001636 |
O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. Fuell | Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease |
| 001654 |
M. T. Herrero [Espagne] ; S. J. Augood [Royaume-Uni] ; H. Asensi [Espagne] ; E. C. Hirsch [France] ; Yves Agid [France] ; J. A. Obeso [Espagne] ; P. C. Emson [Royaume-Uni] | Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys |
| 001713 |
JA-HYUN BAIK [France] ; R. Picetti [France] ; A. Saiardi [France] ; G. Thiriet [France] ; A. Dierich [France] ; A. Depaulis [France] ; M. Le Meur [France] ; E. Borrelli [France] | Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors |
| 001737 |
B. Lannes [France] ; V. Bernard [France] ; B. Bloch [France] ; G. Micheletti [France] | Chronic treatment with dizocilpine maleate increases the number of striatal neurons expressing the D2 receptor gene |
| 001752 |
| Etude neuroanatomique de l'expression du récepteur dopaminergique D2 et de la préproenképhaline dans le striatum de rat après dénervation dopaminergique totale ou partielle et greffe de mésencéphale embryonnaire |
| 001842 |
F. Goulley [France] ; Y. Wolmark [France] ; I. Bourdeix [France] ; P. D. Chaumet-Riffaud [France] | Introduction du Parlodel® en association précoce à la lévodopa dans le traitement de la maladie de Parkinson : comparaison de deux progressions posologiques |
| 001955 |
F. Lisovoski [France] ; C. Haby [France] ; E. Borrelli [France] ; C. Schleef ; M.-O. Revel ; C. Hindelang ; J. Zwiller | Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model |
| 001A16 |
H. Allain ; F. Le Coz ; F. Goulley ; F. Brunet-Bourgin ; Y. Loria ; D. Bentue-Ferrer ; R. Decombe ; J.-M. Reymann ; P. Chaumet-Riffaud ; J.-M. Gandon | Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians : a randomized double-lind crossover study |
| 001A43 |
J. L. Montastruc ; O. Rascol ; A. Rascol | Comparison de la bromocriptine et de la levodopa dans le traitement de première intention de la maladie de Parkinson : résultats à 3 ans d'une étude prospective randomisée |
| 001A51 |
D. Milon [France] ; H. Allain ; J. M. Reymann ; G. Morel ; O. Sabouraud ; J. Van Den Driessche | Randomized double-blind trial of injectable heptaminol for controlling spontaneous or bromocriptine-induced orthostatis hypotension in parkinsonians |
